Plant-derived and semi-synthetic calanolide compounds with anti-human immunodeficiency virus type 1 (HIV-1) activity were tested for antihuman cytomegalovirus (HCMV) activity in both cytopathic effect inhibition and plaque reduction assays. The results indicated that the anti-HCMV activity of calanolide compounds does not correlate with their activity against HIV-1. The semi-synthetic 12-keto derivatives tended to be more active against HCMV than the corresponding 12-OH congeners, which were more active against HIV-1. It appeared that the 7,8-unsaturated double bond in the chromene ring played a certain role in maintaining activities against both HCMV and HIV-1. Saturation of the double bond increased the EC 50 values against both viruses, with concomitant increase in toxicity. The calanolide compounds reported here are the first non-nucleoside analogues capable of inhibiting both HIV-1 and HCMV and, therefore, may be useful chemoprophylactic agents for HCMV in HIV-infected people or vice versa.
Despite advances in antiviral chemotherapeutics, human cytomegalovirus (HCMV), a herpesvirus, infects up to 80% of the general population and remains a major cause of morbidity and mortality in immunocompromised individuals (organ transplant recipients and AIDS patients) (Ho, 1990; Merigan & Resta, 1990) . HCMV causes a broad spectrum of clinical manifestations including retinitis, colitis, oesophagitis, encephalitis, polyradiculopathy, pneumonia, adrenalitis and oral ulcers, with retinitis being the most common manifestation of HCMV disease in human immunodeficiency virus (HIV)-infected patients (Drew, 1992; Goodgame, 1993; Jabs et al., 1989; Jacobson & Mills; 1988; Kalayjian et al., 1993; McCutchan, 1995; Morgello et al., 1987; Schooley, 1990) . HCMV retinitis is a sightthreatening opportunistic infection, which, if left untreated, usually progresses to involve large areas of the retina, resulting in significant or complete vision loss.
Considerable laboratory research has been done to examine the interaction between HIV and HCMV and the potential role of HCMV as a cofactor in HIV-related disease progression. Depending on the cell type or whether the virus can replicate within the cell, a consistent pattern of interaction between these two viruses has been observed. When both viruses can replicate efficiently in the same cell, there is a down-regulation of HIV by HCMV; in contrast, there is an increase in HIV replication when cells are fully permissive for HIV but not for HCMV (Koval et al., 1991; Lathey et al., 1994) . Furthermore, the US28 region of HCMV has been shown to encode a chemokine receptor with similar properties to CCR5, which is critical for HIV infection of macrophages. Expression of the HCMV-encoded chemokine receptor on CD4 cells would permit infection with macrophage-tropic strains of HIV, suggesting that HCMV may facilitate HIV entry into cells (Gao & Murphy, 1994; Pleskoff et al., 1997) .
Introduction
Four antiviral drugs (ganciclovir, foscarnet, cidofovir and fomivirsen) are currently approved for the treatment of HCMV retinitis. Although these drugs are initially effective in delaying the progression of HCMV retinitis, stopping the retinopathy or decreasing retinal inflammation, viral relapse is common (Lalezari et al., 1997; Studies of Ocular Complications of AIDS Research Group, 1997) . Therefore, management of HCMV retinitis is characterized by a cycle of induction therapy (for example, intravenous ganciclovir or foscarnet twice daily) followed by a period of maintenance treatment (for example intravenous ganciclovir or foscarnet daily, or oral ganciclovir three times a day (Walker & Popescu, 1998) . However, each period of reactivation carries the potential for greater retinal destruction and, hence, the threat of vision loss. The emergence of clinical HCMV strains resistant or crossresistant to the approved drugs further limits long-term usage of them (Tatti et al., 1998) . There are also concerns about limited efficacy, the toxicity of each drug, the effect of indwelling catheters required to deliver long-term intravenous therapy on the quality of life of patients and the associated risk of sepsis.
Combination therapy approaches have become the mainstay of treatment for various infectious and neoplastic diseases. Combination of drugs, which target either different stages of the viral life cycle or the same enzyme molecule by different mechanisms, offers many potential advantages over monotherapy, including decreased toxicity if dosages can be reduced, increased efficacy and delayed onset of drug resistance. Although a combination of ganciclovir and forscarnet has shown superior clinical benefits (Butler et al., 1992; Dieterich et al., 1993; Jacobson et al., 1994; Karmochkine et al., 1994) and in vitro anti-HCMV synergy has been observed for other combination regimens (Manion et al., 1996) , all these agents are either nucleoside and nucleotide analogues or pyrophosphate analogues that target the HCMV DNA polymerase by competing with normal nucleotide substrates and acting as DNA chain terminators. One would expect that identification of additional anti-HCMV agents with unique mechanisms of action would allow the development of even more successful therapeutic strategies. If an agent is active against both HIV and HCMV, inclusion in the combination regimen would offer additional benefits to patients who are infected by both viruses. Among the potential benefits is the reduction in pill burden, lowering overall medication cost and improved compliance.
The plant-derived calanolide class of pyranocoumarin compounds has been demonstrated to be active against HIV-1 (Kashman et al., 1992) and (+)-calanolide A, the leading compound in this class (Boyer et al., 1993; Currens et al., 1996a,b; Flavin et al., 1996; Hizi et al., 1993; Sorbera et al., 1999; Xu et al., 1999) , is being evaluated for safety and efficacy in clinical trials (Ruckle et al., 1999) . As part of our continuing interest in pyranocoumarins and in an attempt to identify novel non-nucleoside analogues with activity against both HIV and HCMV, we selected the anti-HIV active calanolides for further evaluation for activity against HCMV.
Materials and Methods
Chemistry (+)-Calanolide A (1) was originally isolated from the dried fruits and twigs of Calophyllum lanigerum var. Austrocoriaceum (Kashman et al., 1992) . It was then chemically synthesized for preclinical and clinical development owing to the scarce supply of natural sources Khilevich et al., 1996) . (-)-Calanolide B (costatolide) (2) was relatively abundant in the latex of C. teysmannii (Lin et al., 1999) or seed oil of C. cerasiferum (Spino et al., 1998) . A scaleable method that has been developed to obtain this compound in sufficient quantities and purities in a low-cost manner was used (Lin et al., 1999) . Soulattrolide (3) was also isolated along with (-)-calanolide B from the latex (Lin et al., 1999) . The 12-keto derivatives, (+)-and (±)-4 as well as (±)-5, were produced either through a total synthesis or by semi-synthesis from Jones oxidation of 1 and 2 (Galinis et al., 1996) . Catalytic hydrogenation of 2 and (+)-4 yielded the corresponding 7,8-dihydro derivatives (-)-6 and (+)-7 (Galinis et al., 1996) (Figure 1 ). All the compounds obtained for testing were at least 96% pure and were characterized by physical, chromatographic and spectroscopic data that was in full agreement with structural assignments and identical to those reported in the literature.
Cytopathic effect inhibition assay against HCMV
Low-passage (3-10) human foreskin fibroblast (HFF) cells were trypsinized, counted and seeded into 96-well tissue culture plates 24 h prior to use at a cell concentration of 2.5×10 4 cells/ml in 0.1 ml of MEM supplemented with 10% foetal bovine serum (FBS). The cells were then incubated for 24 h at 37°C in a 5% CO 2 incubator. The medium was then removed, and 100 µl of MEM containing 2% FBS was added to all except the first row of wells. In the first row, 125 µl of medium containing the drug was added in triplicate wells, which was then diluted serially 1:5 throughout the remaining wells by transferring 25 µl using the Cetus liquid han-dling machine. Medium alone was added to both cell and virus control wells. The plates were then incubated for 1 h and 100 µl of HCMV was added to each well at a concentration of 2500 p.f.u./well, excluding cell control wells, which received 100 µl of MEM. After the plates were incubated at 37°C in a 5% CO 2 incubator for 14 days, medium was aspirated and the cells stained with a crystal violet solution for 30 min. All excess stain was removed by rinsing the plates with tap water. The plates were allowed to dry for 24 h and then read on a BioTek Multiplate Autoreader. Ganciclovir was used as a positive control drug. The drug concentration that inhibited viral replication by 50% (EC 50 ) was calculated by comparing the results from untreated cultures using a computer program.
Plaque reduction assay against HCMV Subconfluent monolayers of HFF cells in 12-well tissue culture plates pregrown in MEM supplemented with 10% heat-inactivated FBS, L-glutamine and gentamicin were exposed to a suspension of HCMV for 2 h at 37°C to allow virus adsorption. The fluids were then removed and the cell layers rinsed with MEM without serum. Triplicate virus-infected cell cultures per drug concentration were each fed with 1.0 ml of overlay medium (MEM and 2% FBS in 0.25% agarose) con-taining drug. The drugs were tested using 4 half-log 10 dilutions ranging from 100 to 0.1 µM. The drugs were dissolved in DMSO, prepared at a 2× concentration in 2× MEM and 4% FBS and mixed with an equal volume of 0.5% agarose in de-ionized water so that the final concentration of overlay medium contained 1× concentration of drug in MEM with 2% FBS and 0.25% agarose. Cell and virus control cultures were overlayed with medium alone. The plates were incubated at 37°C in a 5% CO 2 incubator until plaques were formed (5 days for Towne and Coffman strains of HCMV and 6 days for AD169, E. Mann and C9208 strains of HCMV). The cultures were fixed with 10% formalin and stained with methylene blue. Plaques were counted with the aid of a dissection microscope. Plaque reduction was determined by comparing the mean plaque count of drug-related cultures with the mean plaque number in the untreated virus-infected control cultures and expressed as a percentage.
Cytopathic effect inhibition assay against HIV
The HIV inhibitory activity was evaluated as previously described in a microtitre anti-HIV assay using CEM-SS cells . Thus, CEM-SS cells used for screening were maintained in RPMI 1640 medium supplemented with 10% (v/v) heat-inac- Figure 1 . The chemical structures of plant-derived calanolides tivated foetal calf serum, 100 units/ml penicillin, 100 µg/ml streptomycin, 25 mM HEPES and 20 µg/ml gentamicin. The medium used for dilution of compounds and maintenance of cultures during the assay was the same as above. Cultures were maintained in disposable tissue culture labware at 37°C in a humidified atmosphere of 5% CO 2 in air. The appropriate amounts of the compounds for anti-HIV evaluations were dissolved in 100% DMSO and then diluted with the medium to the desired initial concentration. Each dilution was added to plates at 100 µl/well. Compounds were tested in triplicate wells per dilution. After addition of cells to the plates, the high drug concentration was 100 µg/ml and the high DMSO concentration was 0.25%. Infected cells were charged with HIV-1 virus to yield an approximate multiplicity of infection (m.o.i.) of 0.12 TCID 50 /cell in a volume of 1 ml per 10 6 cells. The cell-virus suspension was incubated at 37°C for 4 h, whereupon the cells were centrifuged and the virus supernatant was discarded. Medium was added to the cells to attain a cell density of 10 5 cells/ml. The infected cells were added to a 96well microtitre plate at 100 µl/well to give a starting cell number of 10 4 cells/ml. After being incubated for 6 days, the cellular viability was then measured with a tetrazolium dye, MTT (5 mg/ml), added to the test plates. The nucleoside reverse transcriptase inhibitor, zalcitabine, was used as a positive control drug. The EC 50 value was calculated.
Evaluation of cytotoxicity
Cytotoxicity of compounds was evaluated in parallel to the antiviral efficacy assays as described above. Uninfected cells, which were prepared in the same manner as the infected cells but without the addition of viruses, were used for the cytotoxicity assay. The quantity of drug that reduced cell viability, as determined by dye uptake, by 50% (CC 50 ) was also calculated.
Results and Discussion
Seven anti-HIV calanolide compounds were initially screened for anti-HCMV activity in the cytopathic effect (CPE) inhibition assay. As can be seen in Table  1 , the anti-HCMV activity of calanolide compounds does not correlate with their activity against HIV-1. For example, (+)-calanolide A (1), the most active anti-HIV-1 compound in this class, was devoid of anti-HCMV activity and (±)-5, being moderately active against HIV-1, exhibited very good activity against HCMV. The structural features required for anti-HCMV activity appeared to be different from that of anti-HIV-1 activity. The compounds with 12-OH groups, for example (+)-calanolide A (1), (-)-calanolide B (2) and soulattrolide (3), tended to be more active against HIV-1, whereas 12-keto derivatives such as (+)-4 and (±)-5 were more active against HCMV, with (+)-4 being most active among the compounds tested. However, it was apparent that the 7,8-unsaturated double bond in the chromene ring played a certain role in maintaining activities against both HCMV and HIV-1. Saturation of the double bond as in (-)-6 and (+)-7 increased the EC 50 values against both viruses, with concomitant increase in toxicity. None of the calanolide compounds demonstrated a significant activity against HIV-2 and the Smith strain of murine CMV (MCMV) in a cytopathic effect inhibition assay (data not shown).
Compounds (-)-2, (+)-4, (±)-5 and (-)-6 were further investigated for anti-HCMV activity in a plaque reduction assay against various laboratory and clinical isolates including Towne, AD169, E. Mann, Coffman and C9208. For comparison, (±)-4 was also evaluated in parallel. All the compounds demonstrated activity against all the strains of HCMV tested ( Table 2 ). The activity levels were comparable to, if not more active than, the positive control drug, ganciclovir. It was some- what surprisingly to see that both (+)-4 and (±)-4 exhibited the same level of activity, which was, however, consistent with their anti-HIV-1 activity (Xu et al., 1998) . These two compounds further distinguished themselves from others by exhibiting less toxicity. These compounds were also screened for activities against other herpesviruses including herpes simplex virus type 1 (HSV-1) and HSV-2, varicella-zoster virus and Epstein-Barr virus (EBV), as well as respiratory viruses including influenza virus A and B, respiratory syncytial virus, parainfluenza 3, adenovirus 5 and measles virus. No significant activities were observed except that (+)-4 exhibited activities against EBV and measles with EC 50 values of 2.6 and 3 µM, whereas soulattrolide (3) exhibited moderate activities against influenza A virus (H1N1) with an EC 50 value of 14 µM.
Calanolide compounds are believed to be inhibitors of the reverse transcriptase (RT) of HIV-1 Kashman et al., 1992; Taylor et al., 1994; Xu et al., 1999) . The inhibition is very specific, with no appreciable activity toward HIV-2 RT, avian myeloblastosis virus RT, cellular RNA polymerase or DNA polymerases α or β (Currens et al., 1996a; Flavin et al., 1996; Pengsuparp et al., 1996) . Unlike other non-nucleoside HIV-1 RT-specific inhibitors, which inhibit HIV-1 RT non-competitively, both (+)-calanolide A (1) and (-)calanolide B (2) inhibited HIV-1 RT by a complex mechanism (Currens et al., 1996b; Buckheit et al., 1999) . Kinetic analysis suggested two binding sites (Currens et al., 1996b) . With respect to either deoxynucleotide triphosphate (dNTP) or template-primer binding, one site was competitive and the other was non-competitive, possibly the common binding pocket for non-nucleoside RT inhibitors (Arnold et al., 1996) . The mechanism of inhibition of HCMV by calanolides has yet to be investigated. One may speculate that these compounds could inhibit HCMV DNA polymerase, either competitively or non-competitively, with minimal effect on other herpesviruses.
In summary, the plant-derived and semi-synthetic calanolide compounds are the first reported non-nucleoside analogues capable of inhibiting both HIV-1 and HCMV and, therefore, may be useful chemoprophylactic agents for HCMV in HIV-infected people or vice versa. 
